Finoriq research workspace
Bone Biologics Corp (BBLG) Historical Metrics
Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides. Review BBLG valuation ratios, fundamentals, and filing metrics on Finoriq.
Company Snapshot
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
- Company
- Bone Biologics Corp (BBLG)
- Ticker
- BBLG
- Market Cap
- $2M
- Latest Price
- $1.13
- Industry
- Industrial Specialties
Bone Biologics Corp (BBLG) Current Valuation Metrics
Static valuation preview for Bone Biologics Corp (BBLG). Market data retrieved 2026-07-08. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -11.0% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -9.9% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 5.57x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.